Company Profile
Pacira BioSciences Stock Price, News & Analysis
Company overview
Business overview
Pacira BioSciences is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Pacira BioSciences is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Pacira BioSciences follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Pacira BioSciences sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
PCRX is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Pacira's next clean milestone is the shoulder study for ZILRETTA. Enrollment is already complete, so the real question now is how the registrational program holds up as it moves toward data. EXPAREL still gives the story some commercial support, but the shoulder readout is the part that can actually change the tone of the name.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: Pacira BioSciences
- 02
Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation
Source: Pacira BioSciences
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.